Skip to main content
. 2022 Jun 6;14(11):2816. doi: 10.3390/cancers14112816

Figure 3.

Figure 3

Kaplan-Meier analysis of the associations of NSCLC survival with KMT2C/BCOR/KDM5C mutations and TMB level with: (AD) patient stratified based on KMT2C/BCOR/KDM5C mutations, (EH) patient stratified based on TMB level (12 mutations/Mb as cutoff), (IL) patient stratified based on a combination of KMT2C/BCOR/KDM5C mutations and TMB level. Four ICB treated cohorts were analyzed, including Hellmann 2018 (A,E,I), Miao 2018 (B,F,J), Rizvi 2018 (C,G,K) and Samstein 2019 cohorts (D,H,L). PFS time was used in survival analysis except for Samstein 2019 in which only overall survival (OS) follow-up data is available.